Imagen de Portada

Editorial: Spontaneous Bacterial Peritonitis—Redrawing Empiric Therapy in the Era of Multidrug Resistance. Authors' Reply

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Rohit Mehtani, Nipun Verma
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Editorial: Spontaneous Bacterial Peritonitis—Redrawing Empiric Therapy in the Era of Multidrug Resistance
por: Apichat Kaewdech, et al.
Publicado: (2026)

Epidemiology, Predictors of Antimicrobial Resistance and Empiric Treatment Strategies for Spontaneous Bacterial Peritonitis in Cirrhosis: A Multicentre SBP ‐ INDIA Study
por: Nipun Verma, et al.
Publicado: (2026)

Editorial: Proton Pump Inhibitors and the Changing Face of Spontaneous Bacterial Peritonitis
por: S. Quickert, et al.
Publicado: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
por: Federica Tavaglione, et al.
Publicado: (2025)

Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors
por: Philip Kitchen, et al.
Publicado: (2026)

Editorial: TIPS in the Era of Aging and Metabolic Comorbidity—Rethinking Risks and Rewards. Authors Reply
por: Michelle Spaan, et al.
Publicado: (2026)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
por: Maral Amangurbanova, et al.
Publicado: (2024)

Editorial: Ulcerative Colitis Management in the Biologic Era–Data From the English Healthcare Databases. Authors' Reply
por: J. Couch, et al.
Publicado: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
por: Eric Lawitz, et al.
Publicado: (2025)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter: Authors' Reply
por: Aakash Desai, et al.
Publicado: (2025)

Spontaneous Bacterial Peritonitis Is Associated With High Mortality, Which Interacts With Antibiotic Prophylaxis in a National Cirrhosis Cohort
por: Scott Silvey, et al.
Publicado: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease? Authors' Reply
por: Nicolas Richard, et al.
Publicado: (2025)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
por: Donghee Kim, et al.
Publicado: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
por: Ramin Ebrahimi, et al.
Publicado: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
por: Shuaibing Ying, et al.
Publicado: (2026)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
por: Jianhui Zhao, et al.
Publicado: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
por: Jeongkuk Seo, et al.
Publicado: (2024)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
por: Máté Szilcz, et al.
Publicado: (2025)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
por: Luis Antonio Díaz, et al.
Publicado: (2025)

Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice. Authors' Reply
por: Kee Huat Chuah, et al.
Publicado: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
por: David Mehdi Asgher Niazi, et al.
Publicado: (2026)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
por: Raj Vuppalanchi, et al.
Publicado: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
por: Fai Fai Ho, et al.
Publicado: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
por: Suprabhat Giri, et al.
Publicado: (2025)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply
por: Ryan M. Mathias, et al.
Publicado: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
por: Parul Tandon, et al.
Publicado: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
por: Bharati Kochar, et al.
Publicado: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
por: Jeffrey D McCurdy, et al.
Publicado: (2025)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
por: Daniel Q. Huang, et al.
Publicado: (2026)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
por: Mary Yue Wang, et al.
Publicado: (2026)

Editorial: The Devil Is in the Detail—Interpreting the Findings of Network Meta‐Analyses. Authors' Reply
por: Mohammad Shehab, et al.
Publicado: (2025)

Editorial: Resecting Assumptions—Do Proctocolectomy Guidelines Hold Up? Author's Reply
por: Erik Lundqvist, et al.
Publicado: (2025)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
por: Lucie Simonis, et al.
Publicado: (2025)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
por: Jiong Yu, et al.
Publicado: (2024)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
por: Ying‐Nan Tsai, et al.
Publicado: (2025)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
por: Carolin V. Schneider, et al.
Publicado: (2024)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply
por: Kee Huat Chuah, et al.
Publicado: (2025)

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease. Authors' Reply
por: Stefano Siboni, et al.
Publicado: (2026)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
por: José Luis Rueda García, et al.
Publicado: (2026)

Editorial: UDCA Dosing in PBC—Between Guideline Adherence and Clinical Reality: Authors' Reply
por: Ellen Werner, et al.
Publicado: (2026)